The Next Phase: Exploring Innovation in Clinical Trials How DCT and AI Are Here to Transform Clinical Trials
9 snips
May 29, 2024 Nael Abdelsamad, a physician and director of research at Cleveland Clinic Abu Dhabi, shares his insights on transforming clinical trials through technology. He discusses the shift towards decentralized clinical trials in the post-pandemic era, highlighting both their potential and the challenges of integration. Nael emphasizes the importance of harnessing AI and machine learning to enhance patient experiences while minimizing administrative burdens. He also addresses the need for streamlined tech solutions and workforce development to foster a more efficient trial landscape.
AI Snips
Chapters
Transcript
Episode notes
Rethinking Decentralized Trials
- Decentralized clinical trials (DCTs) don't mean fully virtual trials but include elements that don't rely on traditional sites.
- Sites felt excluded during the shift to DCTs, and a balanced approach focusing on patient needs is crucial now.
Innovation Follows Gartner Hype Cycle
- Innovation often follows the Gartner hype cycle: initial excitement leads to inflated expectations and eventual disillusionment.
- Both DCT and AI currently face this cycle, so tempered expectations and realistic applications are essential.
Manage Tech Overload Thoughtfully
- Reduce tech overload by consolidating platforms and integrating solutions for a seamless user experience.
- Use AI and machine learning selectively to augment workflows without unnecessary complexity.